AI Insight
New analyses presented at the European Association for the Study of Diabetes (EASD) annual meeting demonstrate that orforglipron, a daily oral GLP-1 medication for weight loss and type 2 diabetes treatment, produced comparable weight loss results across women in three different menopausal stages. The study examined effectiveness in premenopausal, perimenopausal, and postmenopausal women, finding no significant differences in weight loss outcomes based on menopausal status or age.
Why it matters
This finding suggests that hormonal changes associated with menopause may not significantly impact the effectiveness of GLP-1 medications for weight management, providing reassurance that this treatment option can be equally beneficial for women regardless of their reproductive life stage. The oral formulation may offer improved convenience compared to injectable GLP-1 medications currently on the market.
Understand the Science
New analyses to be presented at the annual meeting of the European Association for the Study of Diabetes (EASD) in Milan, Italy, Sept. 28–Oct. 2, show that orforglipron, a daily oral medication for weight loss and type 2 diabetes, was associated with similar weight loss among women of different ages and at different life stages: before, during and after menopause.
Source: Daily oral GLP-1 medication linked to similar weight loss across three menopausal stages